Recruiting Hidradenitis Suppurativa Studies in Palo Alto
Descemet Endothelial Thickness Comparison Trial I
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose...
Descemet Endothelial Thickness Comparison Trial II
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DM...
About Hidradenitis Suppurativa Clinical Trials in Palo Alto
Hidradenitis suppurativa is a chronic skin condition causing painful lumps under the skin, typically in areas where skin rubs together. It can lead to tunnels under the skin and scarring. Treatment includes antibiotics, biologics, and surgical interventions.
There are currently 2 hidradenitis suppurativa clinical trials recruiting participants in Palo Alto, CA. These studies are seeking a combined 220 participants. Research is being sponsored by Stanford University. Clinical trial participation is free and participants receive study-related medical care at no cost.
Hidradenitis Suppurativa Clinical Trials in Palo Alto — FAQ
Are there hidradenitis suppurativa clinical trials in Palo Alto?
Yes, there are 2 hidradenitis suppurativa clinical trials currently recruiting in Palo Alto, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Palo Alto?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.
Are clinical trials in Palo Alto free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.
What hidradenitis suppurativa treatments are being tested?
The 2 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for hidradenitis suppurativa.
Data updated March 2, 2026 from ClinicalTrials.gov